Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03768531 |
| Title | Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer |
| Recruitment | Withdrawn |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries |